13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001381843
Total reported value
$371.7M
$371.7M
36 檔
24.0%
The Q4 2024 SEC filing reveals that Atle Fund Management AB held a total portfolio value of $371.7M, covering 36 public equity positions.
In Q4 2024, Atle Fund Management AB displayed an active expansion posture, initiating 3 new positions and adding to 22 existing holdings, outstripping position reductions.
In terms of portfolio concentration, the top 5 core holdings (including LLY, UNH, ABBV) accounted for 24.0% of total reported equity market value during Q4 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | LLY | Eli Lilly & Co | Stock-Healthcare | 13.60% | +0.95% | +21.28% | |
| 2 | UNH | Unitedhealth Group Inc | Stock-Healthcare | 8.48% | -0.90% | EXIT | |
| 3 | ABBV | Abbvie Inc | Stock-Healthcare | 7.58% | +1.00% | +103.94% | |
| 4 | BSX | Boston Scientific CORP | Stock-Healthcare | 6.56% | -1.18% | +45.26% | |
| 5 | TMO | Thermo Fisher Scientific Inc | Stock-Healthcare | 6.13% | -0.91% | +13.10% | |
| 6 | MRK | Merck & Co. Inc. | Stock-Healthcare | 4.93% | -0.85% | -31.66% | |
| 7 | SYK | Stryker CORP | Stock-Healthcare | 4.41% | -0.53% | +9.38% | |
| 8 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 4.40% | +0.77% | +11.81% | |
| 9 | ALKS | Alkermes plc | Stock-Healthcare | 3.64% | +0.35% | +12.63% | |
| 10 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 3.60% | -1.05% | +30.98% | |
| 11 | COR | Cencora Inc | Stock-Healthcare | 3.47% | +0.24% | -10.92% | |
| 12 | AMGN | Amgen Inc | Stock-Healthcare | 3.37% | -2.81% | EXIT | |
| 13 | ITCIEUR | Intra-cellular Therapies Inc | Stock-Other | 2.82% | — | -15.89% | |
| 14 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 2.40% | -0.16% | +87.09% | |
| 15 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 2.28% | +0.15% | -15.64% | |
| 16 | DXCM | Dexcom Inc | Stock-Healthcare | 2.22% | +0.45% | +11.72% | |
| 17 | HRMY | Harmony Biosciences Holdings | Stock-Other | 1.95% | — | -20.66% | |
| 18 | CAH | Cardinal Health Inc | Stock-Healthcare | 1.72% | -0.03% | +11.56% | |
| 19 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 1.69% | +0.49% | — | |
| 20 | ACLXGBX | Arcellx Inc | Stock-Other | 1.56% | — | +4.58% | |
| 21 | UFPT | Ufp Technologies Inc | Stock-Other | 1.50% | — | +28.32% | |
| 22 | AM6 | Amicus Therapeutics Inc | Stock-Other | 1.46% | — | +18.65% | |
| 23 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 1.34% | -1.34% | +92.83% | |
| 24 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 1.27% | +0.75% | — | |
| 25 | ✓ | Merus N V | Stock-Other | 1.24% | — | +23.35% | |
| 26 | JANX | Janux Therapeutics Inc | Stock-Other | 0.99% | — | — | |
| 27 | ONC | Beone Medicines Ltd-adr | Stock-Other | 0.95% | -1.22% | — | |
| 28 | KRYS | Krystal Biotech Inc | Stock-Healthcare | 0.70% | +0.21% | — | |
| 29 | MREO | Mereo Biopharma Group Pl-adr | Stock-Other | 0.65% | — | +95.00% | |
| 30 | SMMT | Summit Therapeutics Inc | Stock-Other | 0.62% | — | +17.63% | |
| 31 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 0.56% | — | +41.30% | |
| 32 | AUTL | Autolus Therapeutics PLC | Stock-Other | 0.50% | — | +8.41% | |
| 33 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 0.47% | -0.71% | EXIT | |
| 34 | ✓ | Mersana Therapeutics Inc | Stock-Other | 0.36% | — | — | |
| 35 | PHVS | Pharvaris N.V. | Stock-Other | 0.31% | — | — | |
| 36 | CABA | Cabaletta Bio Inc | Stock-Other | 0.26% | — | +46.84% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ABBV | Abbvie Inc | +3.5% | +103.94% | Add |
| 2 | BSX | Boston Scientific CORP | +2.4% | +45.26% | Add |
| 3 | RVMD | Revolution Medicines Inc | +1.3% | NEW | New buy |
| 4 | EW | Edwards Lifesciences CORP | +1.3% | +87.09% | Add |
| 5 | NBIX | Neurocrine Biosciences Inc | +1.1% | +11.81% | Add |
| 6 | JANX | Janux Therapeutics Inc | +1% | NEW | New buy |
| 7 | ONC | Beone Medicines Ltd-adr | +1% | NEW | New buy |
| 8 | LLY | Eli Lilly & Co | +0.9% | +21.28% | Add |
| 9 | BBIO | Bridgebio Pharma Inc | +0.7% | +92.83% | Add |
| 10 | NAMS | NewAmsterdam Pharma Company N.V. | +0.6% | — | Unchanged |
| 11 | DXCM | Dexcom Inc | +0.5% | +11.72% | Add |
| 12 | ALKS | Alkermes plc | +0.5% | +12.63% | Add |
| 13 | SYK | Stryker CORP | +0.4% | +9.38% | Add |
| 14 | CAH | Cardinal Health Inc | +0.3% | +11.56% | Add |
| 15 | MREO | Mereo Biopharma Group Pl-adr | +0.3% | +95.00% | Add |
| 16 | AM6 | Amicus Therapeutics Inc | +0.1% | +18.65% | Add |
| 17 | ✓ | Merus N V | +0.1% | +23.35% | Add |
| 18 | PHVS | Pharvaris N.V. | 0% | — | Unchanged |
| 19 | ACLXGBX | Arcellx Inc | 0% | +4.58% | Add |
| 20 | ITCIEUR | Intra-cellular Therapies Inc | -0.1% | -15.89% | Trim |
| 21 | KRYS | Krystal Biotech Inc | -0.1% | — | Unchanged |
| 22 | VRTX | Vertex Pharmaceuticals Inc | -0.1% | +30.98% | Add |
| 23 | CRBP | Corbus Pharmaceuticals Holdi | -0.1% | +41.30% | Add |
| 24 | CABA | Cabaletta Bio Inc | -0.1% | +46.84% | Add |
| 25 | ✓ | Mersana Therapeutics Inc | -0.1% | — | Unchanged |
| 26 | SLNOEUR | Soleno Therapeutics Inc | -0.2% | +17.24% | Add |
| 27 | AUTL | Autolus Therapeutics PLC | -0.3% | +8.41% | Add |
| 28 | MIRM | Mirum Pharmaceuticals Inc | -0.3% | -15.64% | Trim |
| 29 | TMO | Thermo Fisher Scientific Inc | -0.3% | +13.10% | Add |
| 30 | SMMT | Summit Therapeutics Inc | -0.3% | +17.63% | Add |
| 31 | COR | Cencora Inc | -0.4% | -10.92% | Trim |
| 32 | IMCR | Immunocore Holdings Plc-adr | -0.8% | EXIT | Sold out |
| 33 | HRMY | Harmony Biosciences Holdings | -0.9% | -20.66% | Trim |
| 34 | AMGN | Amgen Inc | -1% | -5.35% | Trim |
| 35 | UFPT | Ufp Technologies Inc | -1.2% | +28.32% | Add |
| 36 | UNH | Unitedhealth Group Inc | -1.3% | -0.81% | Trim |
| 37 | IONS | Ionis Pharmaceuticals Inc | -1.6% | EXIT | Sold out |
| 38 | MRK | Merck & Co. Inc. | -3.3% | -31.66% | Trim |
| 39 | REGN | Regeneron Pharmaceuticals | -3.5% | EXIT | Sold out |
According to official SEC Form 13F filings, Atle Fund Management AB reported a total U.S. public equity portfolio value of $371.7M across 36 disclosed positions in Q4 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
RVMD
市值: $2.7M
Top Position Liquidated / Trimmed
REGN
前期市值: $7.4M
During Q4 2024, Atle Fund Management AB's top holdings by market value included LLY (13.6%)、UNH (8.5%)、ABBV (7.6%). The largest single position, LLY, represented 13.6% of total portfolio value.
In Q4 2024, Atle Fund Management AB made 35 total portfolio adjustments, initiating 3 new buys, adding to 22 positions, trimming 7 holdings, and fully liquidating 3 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.